CEO Interview
Thalia Therapeutics plc announced the release of a video interview with its CEO discussing the company's differentiated approach to developing next-generation RNA therapeutics, particularly a long-acting preclinical candidate for cardiovascular disease that targets both PCSK9 and Lp(a). The interview highlights Thalia's positioning in the expanding RNA therapeutics market and its proprietary delivery technology, Nuvec®, which aims to overcome RNA delivery challenges. The company's focus on genetically targeted approaches for cardiovascular disease is further underscored by recent research in The New England Journal of Medicine.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon, speaking with BioHub.
In the interview, Dr Solomon discusses the significant room for innovation in RNA therapeutics and how Thalia is positioning itself in this rapidly expanding market to develop differentiated next-generation RNA Therapeutics.
In particular, the discussion also explores Thalia's differentiated approach to treating cardiovascular disease, with a long-acting preclinical candidate that addresses two independent risk factors of cardiovascular disease simultaneously, PCSK9 and Lp(a), offering the potential for additive or synergistic benefits.
The interview is available to watch via the Company's website at: https://investors.thaliatx.com/activity-updates/epjN8P-thalia-tx-on-biohub
There is growing interest in genetically targeted approaches to cardiovascular disease and PCSK9-targeted therapies, as reflected in recent clinical research published in The New England Journal of Medicine here: https://www.nejm.org/doi/10.1056/NEJMoa2601283
| Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer | Via Thalia Investor Hub https://investors.thaliatx.com/link/eNbqpe |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang | Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.